Journal of the Bahrain Medical Society
Year 2022, Volume 34, Issue 2, Pages 40-43
https://doi.org/10.26715/jbms.34_2022_2_5Paramesh Sreekumar1, Seemal Maqsood Abdul Qadir2, Neale Nicola Kalis3, Arjun Chandra Dey4
1Department of Pediatrics, King Hamad University Hospital, Bahrain
2Royal College of Surgeon, Ireland-Medical University Bahrain
3Department of Cardiology, Bahrain Defence Force Hospital, Bahrain
4Department of Pediatrics, King Hamad University Hospital, Bahrain
*Corresponding author:
Dr Paramesh Sreekumar, Registrar – Pediatrics, Department of Pediatrics, King Hamad University Hospital, Building 2435, Road 2835. Block 228. P.O Box 24343, Busaiteen, Kingdom of Bahrain; Email: drparamesh_s@rediffmail.com
Received date: July 7, 2021; Accepted date: November 18, 2021; Published date: June 30, 2022
Abstract
Depression in pregnancy is being recognized as a major contributor to adverse maternal and fetal outcomes. Recent years have seen significant research focused on the development of safe pharmacological methods to treat depression in pregnancy, resulting in the common use of selective serotonin reuptake inhibitors (SSRIs) as a first line of treatment. There have been a few reports of congenital birth defects associated with the consumption of SSRIs during pregnancy, particularly congenital heart defects. Several studies have attempted to evaluate the relationship between SSRI use and congenital heart defects in neonates, but they were inconclusive. In this report, a case where maternal SSRI intake during two consecutive pregnancies was associated with neonatal pulmonary valve stenosis, raising the possibility of a correlation between the usage of a certain SSRI, and a particular congenital heart defect has been described.
Keywords: Congenital heart defects, Depression, Pregnancy, Pulmonary valve stenosis, Serotonin uptake inhibitors
Tables and Figures can be referred to in the PDF.